A5050813525- Pharmacogenetics and Drug Metabolism
- Cardiac electrophysiology and arrhythmias
- Acne and Rosacea Treatments and Effects
- DNA and Nucleic Acid Chemistry
- Toxic Organic Pollutants Impact
- Chemical Reaction Mechanisms
- Statistical Methods in Clinical Trials
- Per- and polyfluoroalkyl substances research
- Biosimilars and Bioanalytical Methods
- Atrial Fibrillation Management and Outcomes
- Air Quality and Health Impacts
- Radiopharmaceutical Chemistry and Applications
- Ion channel regulation and function
- Venous Thromboembolism Diagnosis and Management
- Potassium and Related Disorders
National University of Singapore
2021-2023
Agency for Science, Technology and Research
2023
Perfluorooctanoic acid (PFOA) is an environmental toxicant exhibiting a years-long biological half-life (t1/2) in humans and linked with adverse health effects. However, limited understanding of its toxicokinetics (TK) has obstructed the necessary risk assessment. Here, we constructed first middle-out physiologically based toxicokinetic (PBTK) model to mechanistically explain persistence PFOA humans. In vitro transporter kinetics were thoroughly characterized scaled up vivo clearances using...
Rivaroxaban is a viable anticoagulant for the management of cancer-associated venous thromboembolism (CA-VTE). A previously verified physiologically-based pharmacokinetic (PBPK) model rivaroxaban established how its multiple pathways elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs). We...
Background and Purpose Rivaroxaban is emerging as a viable anticoagulant for the pharmacological management of cancer associated venous thromboembolism (CA-VTE). Being eliminated via CYP3A4/2J2-mediated metabolism organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion, rivaroxaban susceptible to drug-drug interactions (DDIs) with protein kinase inhibitors (PKIs), erlotinib nilotinib. Physiologically based pharmacokinetic (PBPK) modelling was applied interrogate DDIs dose...